摘要:
Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.
摘要:
A device and method is disclosed for delivering NO to a patient. The device utilizes a single controller that controls two separate flow controllers to deliver an oxygen-containing gas and a NO-containing gas to the patient to provide NO-containing gas at a flow profile that is proportional or quasi-proportional to a flow profile of the oxygen-containing gas throughout patient inspiration. The controller further comprises logic for setting a nitric oxide delivery profile comprising at least two different concentrations of nitric oxide containing gas and for automatically switching between the at least two different concentrations of nitric oxide containing gas on a timed basis.
摘要:
The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.
摘要:
A method and corresponding device are described for combating microbes and infections by delivering intermittent high doses of nitric oxide to a mammal for a period of time and which cycles between high and low concentration of nitric oxide gas. The high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. The method is advantageous because at higher concentration, nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system. A lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens and also reduces the risk of toxicity of nitric oxide gas.
摘要:
Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.
摘要:
A metered dose inhaler (MDI) spacer has a body that defines a dose receiving chamber. A proximal end portion coupled between the body and a mouth port through which a metered dose may be inhaled by a user of the MDI spacer. A distal end portion is coupled with the body. A combined one-way and flow rate control valve coupled with the distal end portion is configured for permitting external airflow into and prohibiting internal airflow out of the dose receiving chamber. A collar coupled with the distal end portion is configured for receiving an actuator shaft of a metered dose inhaler and for forming a seal about an aerosol nozzle of the metered dose inhaler such that a metered dose of medication is admissible into the dose receiving chamber via the collar while airflow into and out of the dose receiving chamber via the collar is prohibited.
摘要:
The present invention is directed to the administration of aerosolized particles to specific area of the lungs, and in particular to the targeted delivery of aerosolized pharmaceutical formulations to a specific area of the lungs. More specifically, the present invention relates to devices and methods for depositing aerosolized particles to a specific area of the lungs by regulating aerosolizing parameters of the device. The present invention also relates to devices, systems and methods for disease management, where the aerosolizing parameters are adjusted based on monitoring at least one health parameter.
摘要:
Provided is a universal interface adapted for providing continuous positive airway pressure to a patient when the interface is used with a standard ventilator. The interface is configured to operate at a supply pressure no greater than about 120 centimeters of H2O in order to deliver pressure to the patient of up to about 15 cm of H2O at a flow rate of up to about 12 liters/minute. The universal interface may comprise an interface body having a space pair of breathing passageways intersecting a corresponding of supply passageways. Each one of the breathing passageways is comprised of a patient passageway and an exhalation passageway. Each one of the supply passageways includes a jet venturi having a taper portion. Each one of the exhalation passageways includes a taper portion which tapers outwardly along a direction from the patient passageway toward the exhalation passageway.
摘要:
A method of topically treating the respiratory tract of a mammal with nitric oxide exposure includes the steps of providing a source of nitric oxide containing gas and delivering the nitric oxide containing gas nasally to the upper respiratory tract of the mammal. Also provided are several designs for a nasal delivery device for the controlled nasal deliver the nitric oxide containing gas.
摘要:
A respiratory assist device and method for the prevention of ventilator acquired pneumonia in a patient is described. The respiratory assist device administers nitric oxide to the oropharyngeal area in order to decontaminate or prevent the contamination of secretions that collect in the oropharyngeal area during intubation of the patient. The respiratory assist device and method may be adapted for use, for example, as an endotracheal tube or as a tracheotomy tube.